Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma

Abstract

Aim: It remains unclear what the best therapeutic option for recurrent glioma patients after Stupp treatment is. Bevacizumab (BVZ) is commonly administered in progression, but it appears that only some patients benefit. It would be useful to find biomarkers that determine beforehand who these patients are.

Methods: The protocol included 31 high-risk progressing glioma patients after Stupp treatment who received BVZ 5-10 mg/kg every 14 days and temozolomide (3-19 cycles, 150-200 mg five days each 28-day cycle) during a mean of eight cycles of BVZ or until tumor progression or unacceptable toxicity. We analyzed the clinical outcome values of inflammatory indices measured before BVZ administration.

Results: Lymphocyte level before BVZ administration was the best independent predictor of overall survival (HR = 0.34; 95%CI: 0.145-0.81; P = 0.015). The area under the receiver operating characteristic (ROC) curve was 0.823, with 1.645 being the optimal cut-off value, and 0.80 and 0.85 the sensitivity and specificity values, respectively. Responder and non-responder survival curves were also significantly different, considering the first and second tertiles as cut-off points. The number of BVZ cycles was not related to lymphopenia. Pretreatment neutrophil, platelet levels, platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) did not have independent predictive value. Inflammatory variables were not correlated with each other. However, patients with high NLR and PLR simultaneously (double positive PLR-NLR) showed a worse clinical outcome than the rest (P = 0.043).

Conclusion: Pretreatment lymphocyte levels and double positive PLR-NLR could be used as non-invasive hematological prognostic markers for recurrent gliomas treated with bevacizumab. A close relationship emerged between inflammation and angiogenesis.

Keywords

Recurrent glioma / bevacizumab / predictive biomarker / inflammatory indices / lymphocytes

References

[1] Barciszewska AM,Głodowicz P,Naskręt-Barciszewska MZ.A new epigenetic mechanism of temozolomide action in glioma cells..PLoS One2015;10:e0136669 PMCID:PMC4550362

[2] Stupp R,Ostermann Kraljevic S,Maillard I.Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide..J Clin Oncol2002;20:1375-82

[3] Jalbert LE,Phillips JJ,Olson MP.Magnetic resonance analysis of malignant transformation in recurrent glioma..Neuro Oncol2016;18:1169-79 PMCID:PMC4933480

[4] Rempel SA,Ge S.Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma..Clin Cancer Res2000;6:102-11

[5] Brada M,Rampling R,Dirix LY.Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse..Ann Oncol2001;12:259-66

[6] Peak SJ.Role of bevacizumab therapy in the management of glioblastoma..Cancer Manag Res2010;2:97-104 PMCID:PMC3004572

[7] Shao R,Oh DS.Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization..Oncotarget2015;6:40507-18 PMCID:PMC4747349

[8] Gil-Gil MJ,Rey M.Bevacizumab for the treatment of glioblastoma..Clin Med Insights Oncol2013;7:123-35 PMCID:PMC3682734

[9] Nagane M.Dose-dense temozolomide: is it still promising?.Neurol Med Chir (Tokyo)2015;55:38-49 PMCID:PMC4533399

[10] Xu H,Nesvick CL,Ma JY.Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy..Oncotarget2015;6:11882-93 PMCID:PMC4494911

[11] Martínez-González A,Pérez Romasanta LA.Hypoxic cell waves around necrotic cores in glioblastoma: a biomathematical model and its therapeutic implications..Bull Math Biol2012;74:2875-96 PMCID:PMC3510407

[12] Ke Q.Hypoxia-inducible factor-1 (HIF-1)..Mol Pharmacol2006;70:1469-80

[13] Friedman HS,Wen PY,Schiff D.Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma..J Clin Oncol2009;27:4733-40

[14] Koukourakis GV,Zacharias G,Pantelakos P.Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article..Molecules2009;14:1561-77 PMCID:PMC6254280

[15] Takano S,Nakai K,Masumoto T.Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial..Onco Targets Ther2014;7:1551-62 PMCID:PMC4161529

[16] Poulsen HS,Michaelsen SR,Villingshøj M.The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients..Cancer Manag Res2014;6:373-87 PMCID:PMC4186574

[17] Gatson NN,Kaur B.Anti-angiogenic gene therapy in the treatment of malignant gliomas..Neurosci Lett2012;527:62-70 PMCID:PMC3471371

[18] Balañá C,Bugés C.Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?.Clin Transl Oncol2011;13:209-10

[19] Stupp R,van den Bent MJ,Fisher B.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma..N Engl J Med2005;352:987-96

[20] Pérez-Beteta J,Molina D,Luque B.Glioblastoma: does the pre-treatment geometry matter? A postcontrast T1 MRI-based study..Eur Radiol2017;27:1096-104

[21] Molina D,Luque B,Calvo M.Tumour heterogeneity in glioblastoma assessed by MRI texture analysis: a potential marker of survival..Br J Radiol2016;89:20160242 PMCID:PMC5124892

[22] Molina D,Martínez-González A,Peralta S.Geometrical measures obtained from pretreatment postcontrast T1 weighted MRIs predict survival benefits from bevacizumab in glioblastoma patients..PLoS One2016;11:e0161484 PMCID:PMC4996463

[23] Manneh Kopp RA,Ruano Y,Peérez Núñez A.Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab..Clin Transl Oncol2019;21:1413-23

[24] Que Y,Li Y,Xiao W.Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma..BMC Cancer2015;15:648 PMCID:PMC4592563

[25] Feng Z,Bi R,Chen X.Preoperative neutrophil-to-lymphocyte ratio as a predictive and prognostic factor for high-grade serous ovarian cancer..PLoS One2016;11:e0156101 PMCID:PMC4874573

[26] Zhou X,Huang Z,Qiu T.Prognostic value of PLR in various cancers: a meta-analysis..PLoS One2014;9:e101119 PMCID:PMC4072728

[27] D’Emic N,Molitoris J,Sharma NK.Prognostic significance of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients treated with selective internal radiation therapy..J Gastrointest Oncol2016;7:269-77 PMCID:PMC4783753

[28] Templeton AJ,McNamara MG,Vera-Badillo FE.Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis..Cancer Epidemiol Biomarkers Prev2014;23:1204-12

[29] Passardi A,Cavanna L,Tassinari D.Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer..Oncotarget2016;7:33210-9 PMCID:PMC5078087

[30] Templeton AJ,Šeruga B,Aneja P.Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis..J Natl Cancer Inst2014;106:dju124

[31] Alexiou GA,Voulgaris S.Prognostic value of neutrophil-to-lymphocyte ratio in patients with glioblastoma..J Neurooncol2013;115:521-2

[32] McNamara MG,Jiang H,Zadeh G.Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression..J Neurooncol2014;117:147-52

[33] Han S,Li Q,Hou H.Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma..BMC Cancer2015;15:617 PMCID:PMC4559944

[34] Audureau E,Ursu R,Metellus P.Prognostic factors for survival in adult patients with recurrent glioblastoma: a decision-tree-based model..J Neurooncol2018;136:565-76

[35] Bertaut A,Madkouri R,Derangère V.Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma..Oncotarget2016;7:70948-58 PMCID:PMC5342600

[36] Vaios EJ,Muzikansky A,Dietrich J.Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma..Neuro-Oncology Advances2020;2:vdaa031 PMCID:PMC7212859

[37] Bogdanska MU,Piotrowska MJ,Schucht P.A mathematical model describes the malignant transformation of low grade gliomas: Prognostic implications..PLoS One2017;12:e0179999 PMCID:PMC5538650